Interactions of Antidepressants With Neurotransmitter Transporters and Receptors and Their Clinical Relevance

Elliott Richelson

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

This review discusses the pharmacology of antidepressants as it relates to their blockade of human transporters for norepinephrine, serotonin, and dopamine, as well as their blockade of several different human neurotransmitter receptors. This blockade by antidepressants of transporters and receptors is thought to relate to therapeutic and adverse effects of these compounds. Knowledge of the preclinical pharmacology of antidepressants will help the clinician to identify adverse effects and drug interactions that may occur with these agents. The article also reviews drugs that have dual action (effects on serotonin and norepinephrine), which may provide a therapeutic advantage in treating depressed patients.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalJournal of Clinical Psychiatry
Volume64
Issue numberSUPPL. 13
StatePublished - 2003

Fingerprint

Neurotransmitter Transport Proteins
Neurotransmitter Receptor
Antidepressive Agents
Pharmacology
Norepinephrine Plasma Membrane Transport Proteins
Serotonin Plasma Membrane Transport Proteins
Dopamine Plasma Membrane Transport Proteins
Therapeutic Uses
Drug Interactions
Serotonin
Norepinephrine
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Interactions of Antidepressants With Neurotransmitter Transporters and Receptors and Their Clinical Relevance. / Richelson, Elliott.

In: Journal of Clinical Psychiatry, Vol. 64, No. SUPPL. 13, 2003, p. 5-12.

Research output: Contribution to journalArticle

@article{f678e40ba8674c9d9a6e0c7e9e2cdd44,
title = "Interactions of Antidepressants With Neurotransmitter Transporters and Receptors and Their Clinical Relevance",
abstract = "This review discusses the pharmacology of antidepressants as it relates to their blockade of human transporters for norepinephrine, serotonin, and dopamine, as well as their blockade of several different human neurotransmitter receptors. This blockade by antidepressants of transporters and receptors is thought to relate to therapeutic and adverse effects of these compounds. Knowledge of the preclinical pharmacology of antidepressants will help the clinician to identify adverse effects and drug interactions that may occur with these agents. The article also reviews drugs that have dual action (effects on serotonin and norepinephrine), which may provide a therapeutic advantage in treating depressed patients.",
author = "Elliott Richelson",
year = "2003",
language = "English (US)",
volume = "64",
pages = "5--12",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 13",

}

TY - JOUR

T1 - Interactions of Antidepressants With Neurotransmitter Transporters and Receptors and Their Clinical Relevance

AU - Richelson, Elliott

PY - 2003

Y1 - 2003

N2 - This review discusses the pharmacology of antidepressants as it relates to their blockade of human transporters for norepinephrine, serotonin, and dopamine, as well as their blockade of several different human neurotransmitter receptors. This blockade by antidepressants of transporters and receptors is thought to relate to therapeutic and adverse effects of these compounds. Knowledge of the preclinical pharmacology of antidepressants will help the clinician to identify adverse effects and drug interactions that may occur with these agents. The article also reviews drugs that have dual action (effects on serotonin and norepinephrine), which may provide a therapeutic advantage in treating depressed patients.

AB - This review discusses the pharmacology of antidepressants as it relates to their blockade of human transporters for norepinephrine, serotonin, and dopamine, as well as their blockade of several different human neurotransmitter receptors. This blockade by antidepressants of transporters and receptors is thought to relate to therapeutic and adverse effects of these compounds. Knowledge of the preclinical pharmacology of antidepressants will help the clinician to identify adverse effects and drug interactions that may occur with these agents. The article also reviews drugs that have dual action (effects on serotonin and norepinephrine), which may provide a therapeutic advantage in treating depressed patients.

UR - http://www.scopus.com/inward/record.url?scp=0142011218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142011218&partnerID=8YFLogxK

M3 - Article

C2 - 14552650

AN - SCOPUS:0142011218

VL - 64

SP - 5

EP - 12

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 13

ER -